-
Innovation Ranking
NewInnovation Ranking – Hookipa Pharma Inc
Hookipa Pharma Inc (Hookipa) is a clinical-stage biopharmaceutical company that develops novel class of immunotherapeutics against infectious diseases and cancers. Its pipeline products include HB-101, a prophylactic cytomegalovirus vaccine candidate; HB-202 and HB-201, immuno-oncology product candidates for the treatment of human papillomavirus-positive cancers; and HB-301, targeting prostate cancer. Hookipa’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce antigen specific cytotoxic T cells and pathogen-neutralizing antibodies for prophylactic and therapeutic purposes...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HB-101 in Cytomegalovirus (HHV-5) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HB-101 in Cytomegalovirus (HHV-5) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HB-101 in Cytomegalovirus (HHV-5) Infections Drug Details: HB-101 (Vaxwave) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ninsipapogene Sibarnarepvec in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ninsipapogene Sibarnarepvec in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ninsipapogene Sibarnarepvec in Squamous Cell Carcinoma Drug Details: Ninsipapogene sibarnarepvec...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esepapogene Zalarnarepvec in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esepapogene Zalarnarepvec in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esepapogene Zalarnarepvec in Squamous Cell Carcinoma Drug Details: Esepapogene zalarnarepvec...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esepapogene Zalarnarepvec in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esepapogene Zalarnarepvec in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esepapogene Zalarnarepvec in Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esepapogene Zalarnarepvec in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esepapogene Zalarnarepvec in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esepapogene Zalarnarepvec in Oropharyngeal Cancer Drug Details: Esepapogene zalarnarepvec (HB-201, TheraT)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cosibelimab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cosibelimab in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cosibelimab in Metastatic Colorectal Cancer Drug Details: Cosibelimab is under development...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-202 in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HB-202 in Squamous Cell Carcinoma Drug Details: HB-202 is under development for the treatment of...